Not A ‘Gangbusters Launch’ — Arrowhead Predicts Slow Burn to $3-$4B Peak For Redemplo, Highlights ‘Massive Pipeline’
Redemplo is already approved by the U.S. Food and Drug Administration (FDA) to lower very high triglycerides in the rare condition familial chylomicronemia syndrome. The company expects to file a supplemental application seeking approval for Redemplo in severe hypertriglyceridemia by year-end. CEO Chris Anzalone sees $3 billion to $4 billion U.S. peak sales for the … Read more